"id","name","uuid:ID","label","instanceType","description","rationale"
"StudyDesign_1","Study Design 1","3138eb2b-6435-4244-9992-348f7b5c51ee","","StudyDesign","The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
